Radiolabelled antiCD-20 antibodies have demonstrated single agent activity in relapsed diffuse large B-cell lymphoma (DLBCL). The S0433 clinical trial enrolled patients with newly diagnosed, advanced stage or bulky stage II, histologically confirmed DLBCL. Patients received six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles of CHOP, then iodine-131 tositumomab radioimmunotherapy consolidation 30-60 d after completion of chemotherapy. The primary endpoint was 2-year progression-free survival (PFS). Eighty-four eligible patients were enrolled, and 56 patients completed the entire course of protocol treatment. Of the 84 patients evaluable for treatment response, 72 [86%, 95% confidence interval (CI): 76-92%] achieved a partial response (n = 21) or a confirmed (n = 41) or unconfirmed (n = 10) complete response to therapy. With a median follow-up of 3Á9 years, the 2-year PFS estimate is 69% and the 2-year overall survival estimate is 77%. Rituximab levels at time of radioimmunotherapy did not correlate with toxicity or outcome. Twenty percent of patients had double hit features (MYC+; BCL2+) by immunohistochemistry, and had inferior outcome. These current results suggest that the incorporation of novel agents earlier in therapy may ultimately have greater impact in DLBCL, as early progressions, deaths and declining performance status during CHOP chemotherapy limited the number of patients who ultimately could benefit from radioimmunotherapy consolidation.
We therefore designed the S0433 clinical trial, which incorporated consolidative radioimmunotherapy with the 131 I tositumomab regimen after standard R-CHOP chemotherapy for patients with newly diagnosed DLBCL. The objective of trial S0433 was to estimate the 2-year PFS, in hope of increasing the durable remission rate in patients with aggressive lymphomas, without serious additive toxicity.
Methods

Study registration
This Phase II multicentre trial was initiated in November 2005. The protocol was approved by the Institutional Review Board at each site, and written consent was obtained from all patients prior to enrollment. The study was registered with ClinicalTrials.gov prior to enrolling patients (ClinicalTrials.gov Identifier: NCT00107380).
Eligibility
The original trial design limited patient inclusion to those >60 years of age; after 17 (20% of total) patients were enrolled, an amendment expanded the study inclusion criteria to include patients >18 years of age after a competing study for younger patients completed accrual. Eligible patients had a previously untreated diagnosis (World Health Organization classification) of CD20-positive advanced stage (Stage III, IV, or bulky [>10 cm] Stage II) DLBCL with bidimensionally measurable disease; all pathology was confirmed by central review. Eligible patients had adequate performance status (Zubrod 0-2) and adequate renal, hepatic, haematologic, and cardiac function. Baseline laboratory parameters included circulating lymphoid cells <20 9 10 9 /l.
Patients were excluded if they had a previous diagnosis of malignancy (with the exception of basal cell or squamous cell of the skin, in situ cervical cancer, adequately treated Stage I or II cancer for which patient was in complete remission, or any other cancer from which patient had been disease-free for at least 5 years); or clinical evidence of central nervous system (CNS) involvement by lymphoma. Pregnant or nursing female patients, patients known to be human immunodeficiency virus (HIV) positive or with a history of solid organ transplantation, and patients requiring continuous supplemental oxygen therapy, were also excluded.
Baseline studies
Baseline evaluation included a history and physical examination, radiographic imaging (computerized tomography of the chest, abdomen, and pelvis), routine laboratory studies, bone marrow evaluation and an electrocardiogram.
Protocol treatment
Patients were treated with standard R-CHOP chemotherapy as follows: every 21 d for the first 6 cycles (Coiffier et al, 2002) ; rituximab was omitted from cycles 7 and 8 to limit antigen binding competition as observed in murine studies (Gopal et al, 2008) .
131
I tositumomab (Bexxar; supplied by GlaxoSmithKline, Research Triangle Park, NC) was administered 30-60 d after cycle 8 of CHOP, as described (Press et al, 2003) . Intrathecal methotrexate was allowed at physician discretion for CNS prophylaxis. Patients were removed early from the protocol treatment for progressive disease, unacceptable toxicity, failure to meet criteria for tositumomab administration following completion of CHOP chemotherapy, or patient preference.
Criteria for response and toxicity
Restaging for response determination was performed within 4 weeks of the last cycle of CHOP (approximately Day 169), and then again at 12 weeks post-131 I tositumomab treatment using the same imaging techniques used for baseline measurements. Clinical responses were coded according to International Workshop NHL criteria (Cheson et al, 1999) . National Cancer Institute Common toxicity criteria version 3.0 was used to grade toxicities (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf[ctep.cancer.gov]). Patients were followed prospectively and evaluated at 1 year, then every 6 months for 2 years, then annually for a maximum of 5 years. PFS was calculated from the first dose of study drug to the first documentation of disease progression or death due to any cause, whichever occurred first. Patients who were alive and progression-free at the time of final data analysis were censored at last assessment.
Correlative laboratory studies
Rituximab levels and toxicity. We utilized ELISA-0145-004, a sandwich enzyme-linked immunosorbent assay (ELISA) for the determination of Rituximab in human serum after cycle 8 of CHOP. The association between rituximab levels and toxicity were evaluated by comparing the proportion of patients with grade 3, 4 or 5 toxicities for patients with rituximab levels above versus below the median rituximab concentration using chi-square analysis.
Immunohistochemistry. We evaluated MYC and BCL2 protein expression and germinal center B-cell-like (GCB) versus non-GCB status using immunohistochemistry techniques on patient samples obtained at baseline. Studies of MYC expression were performed and scored (40% cut-off; based on minimum 100 cell count) as described (Johnson et al, 2012 (Hans et al, 2004) .
Statistical analysis
For the primary objective, a modified intent-to-treat analysis was performed, excluding patients determined to be ineligible. Patients who did not receive any treatment were excluded from evaluation of adverse events. The primary endpoint of this study was the 2-year PFS rate. The planned statistical design anticipated that 80 patients accrued over 15 months with 18 months of additional follow-up would be sufficient to estimate the 2-year PFS to within AE 0Á12. The design also specified an adjustment for important prognostic groups. We assumed that 2-year PFS was approximately 60% for patients older than 60 years and for younger patients (≤60 years old) with high IPI scores (2 or higher), and approximately 85% for patients ≤60 years with low IPI scores (0 or 1) (Pfreundschuh et al, 2006) . If 10% of patients were in the younger patient group (≤60 years old) with low IPI, the weighted 2-year PFS for R-CHOP would be 63%, compared to an alternative 20% greater (83%). Under these assumptions, an estimated 2-year PFS of 73% or greater [based on the 95% upper bound on the confidence interval (CI) using a one-arm survival design] would be sufficient to warrant further investigation (Lawless, 1982) . The target value was adjusted based on the observed frequency of prognostic groups. Eighty patients would also be sufficient to estimate the probability of any particular toxicity to within AE 0Á11. Survival was estimated according to the method of Kaplan and Meier (Kaplan & Meier, 1958) . Analyses of survival differences by prognostic factors were performed using Cox regression (Cox, 1972) . Landmark survival analyses were conducted for the subset of patients completing all therapy, to avoid selection bias (Anderson et al, 1983) . Data as of August 20, 2013 were included in the analysis.
Results
Patient characteristics
Between November 2005 and March 2010, 86 patients were registered (Fig 1) . Two patients were determined to be ineligible before treatment (one incorrect histology; one CD20-negative disease). Baseline clinical characteristics are detailed in Table I .
Treatment
Fifty-six patients (67%) completed the entire course of protocol treatment (RCHOP + radioimmunotherapy) as planned. Reasons for early termination included: toxicity (n = 8 due to left ventricular ejection fraction changes and neuropathy; infection, backache, and neuropathy; drop in ejection fraction; infection and neuropathy; thrombocytopenia; fatigue; pancytopenia and cirrhosis); refusal unrelated to adverse events (n = 8), progressive disease (n = 4); death (n = 3), institutional error (n = 3) and physician decision (n = 2). Patients who did not receive the full course of RCHOP/ 131 I tositumomab were more likely to have highintermediate/high IPI risk disease compared to those who did receive the entire course of planned therapy (64% vs. 34%; P = 0Á008).
Safety
Five patients experienced Grade 5 toxicities: cardiac ischaemia (n = 2), febrile neutropenia (n = 1), renal failure (n = 1) and secondary malignancy (acute myeloid leukaemia, n = 1). Forty-six additional patients (55%) had at worst Grade 4 toxicity, mostly haematological, as detailed in Table II . Common non-haematological adverse events, occurring in at least 10% of treated patients, are detailed in Table II .
Efficacy
Of the 84 patients evaluable, 72 (86%, 95% CI: 76-92%) achieved an objective response to therapy, including partial response (n = 21) or a confirmed (n = 41) or unconfirmed (n = 10) complete response based upon prespecified criteria (Cheson et al, 1999) . One additional patient maintained stable disease. Among the 56 patients that received all treatment, including 131 I tositumomab, 55 (98%, 95% CI: 90-100%) achieved a partial or complete response to therapy.
The median follow-up of the patients still alive is 3Á9 years. Figure 2 includes the PFS and OS experience of this cohort. Eight patients (10%) were <60 years with low IPI. Therefore the weighted target PFS was 73%. The observed 2-year PFS estimate was 69% (95% CI: 59-79%; Fig 2) . The 2-year OS estimate was 77% (95% CI: 68-86%). Among the 56 patients that received all CHOP-R/ 131 I tositumomab, the 2-year PFS, beginning from 6 months after registration (i.e. after completion of tositumomab treatment using landmark analysis), was 75% (95% CI: 64-86%; Fig 3) .
Correlative laboratory studies
Circulating rituximab levels at day 169. Serum rituximab levels following the eighth cycle of CHOP (drawn at day 169) were studied in 15 patients. Concentration values ranged from 19 100 to 110 000 ng/ml, with a median concentration = 53 500 ng/ml. The proportion of patients with rituximab levels above the group median that experienced Grade 3-4 toxicities was 100% as compared to 86% Grade 3-5 toxicities among the patients with circulating rituximab levels below the group median at Day 169 (P = 0Á47).
MYC and BCL2 immunohistochemistry. 
GI, gastrointestinal. *Two cardiac ischaemia, 1 febrile neutropenia, 1 renal failure, 1 acute myeloid leukaemia. CI: 59%, 83%). Despite a trend, neither PFS nor OS were significantly associated with double protein positive status (P = 0Á34, and P = 0Á99, respectively).
GCB versus non-GCB status. Of the 22 patients evaluated for GCB status, 9 (41%) were GCB and 13 (59%) patients were non-GCB: 6 (67%) GCB and 10 (77%) non-GCB patients completed full protocol treatment. The estimated 2-year PFS in GCB patients and non-GCB patients was 67% (95% CI: 28%, 88%); and 85% (95% CI: 51%, 96%), respectively. Neither PFS nor OS were significantly associated with GCB versus non-GCB status (P = 0Á97, and P = 0Á56, respectively).
Discussion
In our clinical trial, a consolidation strategy utilizing 131 I tositumomab after eight cycles of CHOP chemotherapy (6 with rituximab) for DLBCL did not meet our predefined threshold (2 year PFS = 73%) for future evaluation. Unlike our previous experiences in follicular lymphoma (Press et al, 2003 , in this population of DLBCL, early progressions, deaths and declining performance status during R-CHOP chemotherapy prevented over one quarter of patients from receiving planned consolidation with radioimmunotherapy. For those selected patients who were able to received radioimmunotherapy, the outcome appeared quite favourable, however this group had lower IPI scores, and more favourable clinical characteristics compared to the group of patients who did not receive radioimmunotherapy.
Our results stand in contrast to the limited number of other trials that used radioimmunotherapy as consolidation after initial chemo-immunotherapy for DLBCL. Zinzani initially demonstrated feasibility of this concept in a pilot trial of 20 patients treated with six cycles of CHOP (no rituximab), followed by ibritumomab tiuxetan consolidation, demonstrating safety and efficacy (Zinzani et al, 2008) . The same group then conducted a larger phase 2 trial in 55 highrisk elderly patients of an abbreviated (four cycles) course of R-CHOP followed by ibritumomab tiuxetan consolidation (Zinzani et al, 2010) . Only seven patients (13%) did not receive planned radioimmunotherapy after abbreviated R-CHOP, all due to disease progression. The authors reported an estimated PFS of 85% at 2 years for the entire study population. Hamlin et al (2010) , presented preliminary results of a single institution phase 2 study in elderly patients with DLBCL, utilizing six cycles of R-CHOP followed by ibritumomab tiuxetan consolidation (Hamlin et al, 2010) . Of 63 patients enrolled, 19 (30%) did not receive planned radioimmunotherapy. Similar to our trial, the group of patients who were able to receive radioimmunotherapy had superior outcome. Finally, the Southwest Oncology Group (SWOG) has presented preliminary results of an approach for early stage DLBCL utilizing three cycles of CHOP (no rituximab), involved field radiation therapy, and ibritumomab tiuxetan consolidation, demonstrating higher response rates and longer PFS than historical controls without radioimmunotherapy .
All of these other trials have utilized ibritumomab tiuxetan instead of 131 I tositumomab as the radioimmunotherapy consolidation strategy. Although there are clear differences between these agents, the clinical outcomes across various histologies of lymphomas have been remarkably similar when using either agent (Schaefer-Cutillo & Friedberg, 2008). Perhaps more importantly, these other studies utilized a shorter course of chemotherapy induction prior to consolidation. Although the pivotal studies of the R-CHOP regimen in advanced DLBCL utilized eight cycles of chemotherapy (Feugier et al, 2005) , many experts now prefer six cycles as standard treatment, based in part upon the German experience demonstrating equivalence of 6 versus 8 cycles of R-CHOP given every 14 d (Pfreundschuh et al, 2008) . Given that many patients in our study were not able to receive consolidation with radioimmunotherapy due to frailty and toxic effects of chemotherapy, a shorter course of induction therapy may have provided a more favourable outcome.
Preclinical studies in mice have suggested that rituximab concentrations can block the binding of a second anti-CD20 monoclonal antibody, and therefore circulating rituximab might impair the clinical efficacy of anti-CD20 radioimmunotherapy (Gopal et al, 2008) . For this reason, we omitted rituximab for the seventh and eighth cycles of R-CHOP in our study. Despite this, rituximab levels performed in a subset of patients demonstrated wide variability of circulating rituximab prior to radioimmunotherapy administration. Targeting alternative antigens on DLBCL overcomes this theoretical concern, and a preliminary study of 64 patients with relapsed lymphoma demonstrated safety and efficacy of anti-CD22 fractionated radioimmunotherapy with epratuzumab tetraxetan (Morschhauser et al, 2010) . Other alternative means of delivering radioimmunotherapy include pretargeting using streptavidin-biotin technology, which in model systems has demonstrated superior biodistribution, more complete tumour regressions, and longer survival compared with conventional radioimmunotherapy (Green et al, 2007) . Finally, the Mayo Clinic group has demonstrated impressive results when combining a Toll-like receptor 9 agonist, which has demonstrated activity in combination with rituximab (Friedberg et al, 2005 (Friedberg et al, , 2009 , with ibritumomab tiuxetan in patients with relapsed lymphoma (Witzig et al, 2013) .
DLBCL is a heterogeneous disease, and gene expression profiling studies have identified at least three unique cell-oforigin profiles with differential therapeutic outcomes (Lenz et al, 2008) . In our study, using immunohistochemistry as a surrogate for cell-of-origin, patients with non-GCB lymphoma had equivalent outcome to patients with GCB histology. Recent data has suggested that perhaps the major unmet clinical need in treatment of DLBCL is to overcome the adverse prognostic impact of "double hit" histology, defined by dual overexpression of MYC and BCL2 in DLBCL (Friedberg, 2012) . When measured by immunohistochemistry (double protein positive), up to 30% of newly diagnosed DLBCL can be identified, which portends a dismal prognosis after R-CHOP treatment (Green et al, 2012; Johnson et al, 2012) . The majority of patients with double hit features are elderly, and new treatments are clearly indicated for this group (Pfreundschuh, 2012) . In our study, the observed rates of PFS in the 20% of patients with double protein positivity appeared inferior, which was partly due to early progressions prior to planned radioimmunotherapy.
A recent trial in relapsed or refractory DLBCL comparing rituximab and BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy conditioning to 131 I tositumomab and BEAM chemotherapy conditioning prior to ASCT showed no improvement when radioimmunotherapy was added to the conditioning regimen (Vose et al, 2013) . GlaxoSmithKline (Philadelphia, PA, USA) has announced that, effective from February 2014,
131
I tositumomab will no longer be commercially available in the United States. Ibritumomab tiuxetan remains commercially available, and indeed a phase 3 trial is planned to definitively evaluate the role of radioimmunotherapy consolidation in DLBCL. Based upon our results, favourable prognosis patients without double hit histology may benefit the most from this modality. For patients with high clinical risk features, or double hit features by immunohistochemistry, alternative approaches including the early incorporation of novel agents is preferable to a consolidation or maintenance approach, due to the high rate of early disease progression. Currently, SWOG is evaluating standard R-CHOP chemotherapy with vorinostat (Crump et al, 2008) in advanced stages of DLBCL, and other groups are exploring lenalidomide (Chiappella et al, 2013) and ibrutinib (Younes et al, 2013) in combination with R-CHOP. Moving forward, as our biological understanding of DLBCL improves, rational incorporation of novel approaches, including radioimmunotherapy, should be based upon biological disease signatures rather than empiricism (Friedberg, 2011) .
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